Margaux Wooster

ORCID: 0000-0003-3957-6093
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Breast Cancer Treatment Studies
  • Salivary Gland Tumors Diagnosis and Treatment
  • Head and Neck Cancer Studies
  • Global Cancer Incidence and Screening
  • Ear and Head Tumors
  • Childhood Cancer Survivors' Quality of Life
  • Urologic and reproductive health conditions
  • Acute Lymphoblastic Leukemia research
  • Economic and Financial Impacts of Cancer
  • Prostate Cancer Diagnosis and Treatment
  • Genital Health and Disease
  • Cancer survivorship and care
  • Cancer Treatment and Pharmacology
  • Brain Metastases and Treatment
  • Facial Nerve Paralysis Treatment and Research
  • Cancer Cells and Metastasis
  • Meningioma and schwannoma management
  • Tryptophan and brain disorders
  • Metabolism, Diabetes, and Cancer
  • Cancer Immunotherapy and Biomarkers
  • Adolescent and Pediatric Healthcare
  • Lung Cancer Research Studies
  • Neutropenia and Cancer Infections
  • Multiple and Secondary Primary Cancers
  • Trigeminal Neuralgia and Treatments

Columbia University Irving Medical Center
2021-2024

Atrium Health Wake Forest Baptist
2017-2023

Columbia University
2021

Wake Forest University
2019-2020

Tisch Hospital
2018

Tisch Cancer Institute
2018

Icahn School of Medicine at Mount Sinai
2018

University of Colorado Denver
2014

Georgetown University
2012-2013

MedStar Georgetown University Hospital
2013

Effective short-term outcomes have been well documented for trigeminal neuralgia (TN) patients treated with Gamma Knife radiosurgery (GKRS) reported success rates of 70-90 % median follow-up intervals 19-75 months. Fewer series, however, described uniform long-term data. In this study, we report our institutional in GKRS after a minimum 36 months.Thirty-six consecutive medically intractable TN received radiation dose 45 Gy applied single 4-mm isocenter to the affected nerve. Follow-up data...

10.1007/s13566-013-0134-3 article EN cc-by Journal of Radiation Oncology 2013-11-19

PURPOSE: The purpose of this study was to review a single-institution experience with the reirradiation recurrent salivary gland tumors using fractionated stereotactic radiosurgery (SBRT). METHODS: Between 2003 and 2011, 18 patients diagnosed recurrent, previously irradiated, carcinomas were treated SBRT reirradiation. Median age 68 for all most being major origin. Most did not undergo surgical resection, among those that did, had positive margins. Only seven received chemotherapy, median...

10.1007/s13566-012-0010-6 article EN cc-by Journal of Radiation Oncology 2012-02-18

102 Background: Pathologic complete response (pCR) is used as a surrogate endpoint for overall survival (OS) in high-risk early-stage breast cancer (BC). pCR rates vary according to BC molecular subtype and have the highest association with OS triple negative (TNBC) HER2-positive (HER2+) BC. In these subgroups, neoadjuvant chemotherapy (NACT) often standard of care. We evaluated delays NACT initiation (NACTI) pCR. Methods: conducted retrospective cohort study using National Cancer Database....

10.1200/op.2024.20.10_suppl.102 article EN JCO Oncology Practice 2024-09-30

e13561 Background: Delays in time from breast cancer (BC) diagnosis to BC treatment initiation (BCTI) including upfront surgery (UBS) or neoadjuvant chemotherapy (NACT), can negatively impact survival. We evaluated odds of delay BCTI among patients (pts) who received NACT compared pts UBS. Methods: conducted a retrospective cohort study using the National Cancer Database. Eligibility included age ≥18 years, non-metastatic between 1/1/2010 – 12/31/2020, were treated with followed by UBS...

10.1200/jco.2024.42.16_suppl.e13561 article EN Journal of Clinical Oncology 2024-05-29

Patients with high risk salivary gland malignancies are at increased of local failure. We present our institutional experience dose escalation using hypofractionated stereotactic body radiotherapy (SBRT) in a subset this rare disease. Over the course 9 years, 10 patients presenting skull base invasion, gross disease one or more adverse features, those treated adjuvant radiation three pathologic features were intensity-modulated therapy followed by SBRT boost. presented variable tumor...

10.3389/fonc.2014.00268 article EN cc-by Frontiers in Oncology 2014-10-21

to review a single-institution experience with the management of parotid malignancies treated by fractionated stereotactic body radiosurgery (SBRT).Between 2003 and 2011, 13 patients diagnosed were adjuvant or definitive SBRT median dose 33 Gy (range 25-40 Gy). There 11 male two female age 80. Ten declined conventional radiation treatment three had received prior unrelated therapy neighboring structures unavailable records. Six intent while seven adjuvantly for adverse surgical pathologic...

10.3389/fonc.2012.00055 article EN cc-by Frontiers in Oncology 2012-01-01

11091 Background: Breast cancer (BC) rates are increasing in young adults (YAs: age 18-39) and this population may experience unique barriers to treatment initiation. We identified factors associated with initiation delays a cohort of YAs operable BC who received neoadjuvant chemotherapy (NACT). Methods: Using the National Cancer Database, we diagnosed non-metastatic from 2010-2020 NACT. grouped patients by receptor status clinical stage: 1) Hormone Receptor positive/HER-2 negative...

10.1200/jco.2024.42.16_suppl.11091 article EN Journal of Clinical Oncology 2024-06-01

11012 Background: Clinical trials of novel therapies should enroll a population that reflects patients (pts) who might receive the drug upon FDA approval. In 2017 ASCO proposed modifications to common eligibility criteria (EC) increase generalizability trial findings. Despite this, barriers enrollment in recent era molecularly-targeted are not well-characterized. We examined cohort non-small cell lung cancer (NSCLC) pts with KRAS G12C mutations determine whether EC for inhibitors allowed...

10.1200/jco.2024.42.16_suppl.11012 article EN Journal of Clinical Oncology 2024-06-01

e24134 Background: Diabetes (DM) and hyperglycemia (HG) during chemotherapy increase the risk of treatment-related toxicities. The prevalence HG daily patterns over course in patients with early-stage breast cancer (ESBC) are currently unknown. Methods: We conducted a prospective single-arm pilot study continuous glucose monitoring ESBC receiving from 12/2020 – 2/2022. Eligibility criteria included: diagnosis Stage I-III BC, age ≥18, planned concurrent corticosteroid supportive care use....

10.1200/jco.2024.42.16_suppl.e24134 article EN Journal of Clinical Oncology 2024-06-01

126 Background: Delays in neoadjuvant chemotherapy initiation (NACTI) after breast cancer (BC) diagnosis have been associated with worse outcomes. We evaluated incidence and predictors of delays NACTI among high clinical risk patients treated NACT on a national level. Methods: conducted retrospective cohort study using the National Cancer Database. Eligibility included age ≥18 years, non-metastatic BC between 1/1/2010 – 12/31/2020, who were within 180 days diagnosis. Patients received...

10.1200/op.2024.20.10_suppl.126 article EN JCO Oncology Practice 2024-09-30

100 Background: Delays in time from breast cancer (BC) diagnosis to BC treatment initiation (BCTI) including upfront surgery (UBS) or neoadjuvant chemotherapy (NACT), can negatively impact survival. We evaluated odds of delay BCTI among patients (pts) who received NACT compared pts UBS. Methods: conducted a retrospective cohort study using the National Cancer Database. Eligibility included age ≥18 years, non-metastatic between 1/1/2010 – 12/31/2020, were treated with followed by UBS adjuvant...

10.1200/op.2024.20.10_suppl.100 article EN JCO Oncology Practice 2024-09-30

e13541 Background: Delays in neoadjuvant chemotherapy initiation (NACTI) after breast cancer (BC) diagnosis have been associated with worse outcomes. We evaluated incidence and predictors of delays NACTI among high clinical risk patients treated NACT on a national level. Methods: conducted retrospective cohort study using the National Cancer Database. Eligibility included age ≥18 years, non-metastatic BC between 1/1/2010 – 12/31/2020, who were within 180 days diagnosis. Patients received...

10.1200/jco.2024.42.16_suppl.e13541 article EN Journal of Clinical Oncology 2024-05-29

Abstract Introduction: Diagnosis of leptomeningeal metastasis (LM) is limited by low sensitivity cerebrospinal fluid (CSF) cytopathology. Detecting circulating tumor cells (CTCs) in CSF might be more sensitive. We evaluated if TargetSelector™ (TS), a novel assay that captures CTCs peripheral blood, detects CSF. Methods: enrolled adults with metastatic solid tumors or primary CNS malignancies and clinical suspicion for LM to undergo lumbar puncture (LP) cytopathology TS. TS captured using...

10.21203/rs.3.rs-206232/v1 preprint EN cc-by Research Square (Research Square) 2021-02-18

Abstract Background Prostate abscess (PA) is uncommon and the diagnosis often delayed or missed. Traditionally, PA has resulted from acute prostatitis ascending genitourinary (GU) infection due to gram-negative bacilli but S. aureus an emerging cause. Methods A retrospective review of all adult patients admitted with ICD-9 -10 between January 2013 July 2018 was conducted. Inclusion criteria included age ≥18 years, a compatible GU syndrome, imaging consistent PA. Results Twenty-two were...

10.1093/ofid/ofz360.1312 article EN cc-by-nc-nd Open Forum Infectious Diseases 2019-10-01
Coming Soon ...